Pharvaris to Present Clinical Data of PHA121 for the Treatment of Hereditary Angioedema at the 2021 AAAAI Annual Meeting

ZUG, Switzerland, Feb. 1, 2021 /PRNewswire/ — Pharvaris, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary…

About the Author

has written 21630 stories on this site.

Copyright © 2010-2019 strategicbusinessnews.com